The latest call
FetchingPAVmed Inc. reported on 13 novembre 2026. We are fetching the call transcript; its summary follows once the transcript is in.
1,53 USD+15,0%chiusura 13 nov
The latest quarter (ended 30 settembre 2026) is from PAVmed’s earnings press release of 13 novembre 2026. It will be replaced by the official quarterly report (10-Q) once PAVmed files it.
| Misura | 3 mesi al30 set 2026 | 3 mesi al30 set 2025 | Variazione |
|---|---|---|---|
| Ricavi totali | 41K USD | 5K USD | +720,00% |
| Utile | -11,8M USD | -5,4M USD | -118,32% |
Questi sono singoli trimestri, non un anno mobile: le cifre altrove sul sito coprono dodici mesi e saranno molto più grandi. Un’attività stagionale oscilla parecchio tra i due: ServiceNow genera 2,0 mld $ di flusso di cassa libero nel trimestre di dicembre e 0,5 mld $ in quello di giugno.
Confrontato con lo stesso trimestre di un anno prima, non con una previsione degli analisti. Un «beat» o un «miss» richiede una stima di consenso, che è un dato in licenza che non abbiamo — e sbagliarla è peggio che ometterla.
PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard ® Esophageal DNA Test and EsoCheck ® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.
La descrizione dell’azienda stessa, come compare in calce al comunicato.
The quote, the company description and the latest quarter come from PAVmed’s earnings press release (an Item 2.02 8-K) filed 13 novembre 2026. Earlier quarters come from its quarterly and annual reports, and the latest will be replaced once the official report is filed. Leggi il comunicato su EDGAR I prezzi sono rettificati per frazionamenti e dividendi.
PAVmed Inc. reported on 13 novembre 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Just reported
From PAVmed Inc.'s results release of 13 novembre 2026. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Actual
41K USD
+24% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.